ARTEMIS: RAVULIZUMAB TO PROTECT PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) FROM CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY (CSA-AKI) AND SUBSEQUENT MAJOR ADVERSE KIDNEY EVENTS (MAKE): A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
- Registry ID
- ALXN1210-CSA-AKI-318
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ALEXION PHARMACEUTICALS INC
- Start date
- 2024-06-10
- Last update
- 2022-12-14
Conditions
- CARDIAC SURGERY
- MAJOR ADVERSE KIDNEY EVENTS
- CHRONIC KIDNEY DISEASE (CKD)
Related clinical trials
- A PHASE IIB, RANDOMISED, MULTICENTRE, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH BAXDROSTAT ON ALBUMINURIA IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY
TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
- A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION
TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF EMPAGLIFLOZIN TABLETS IN
PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE (EMPA-KIDNEY® KIDS)
- AUTO-PLTS: THE EFFECTIVENESS OF AUTOLOGOUS, COLD-STORED PLATELETS
COLLECTED 7-10 DAYS BEFORE CARDI-AC SURGERY FOR AVOIDANCE OF
ALLOGENEIC TRANSFUSIONS: A RANDOMIZED PATIENT PREFERENCE TRIAL
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ALONE ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE (BAXDUO-PACIFIC)
- STUDIES OF HEART & KIDNEY PROTECTION WITH BI 690517 IN COMBINATION WITH
EMPAGLIFLOZIN: A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE ALDOSTERONE SYNTHASE INHIBITOR BI 690517 IN
COMBINATION WITH EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE
View on source registry